Also published as: Sung-Hou Kim, H S Kim, Suhyung Kim, Jong-Ho Kim, Mi Ok Kim, Jong Heon Kim, S Y Kim, Chul-Hong Kim, Do Hyung Kim, Sydney Y Kim, Sung Young Kim, So Young Kim, Yeonsoo Kim, Chongtae Kim, Jiha Kim, Myung-Sunny Kim, Hyeong-Rok Kim, Young-Youn Kim, Hye Yun Kim, Miri Kim, Dong Il Kim, Hyeon-Ah Kim, Arie Kim, Esther Kim, Ok-Hwa Kim, Sun-Hee Kim, Juyong B Kim, Joong-Seok Kim, Jong Woo Kim, Saerom Kim, Wondong Kim, Seong-Hyun Kim, Misung Kim, Min Wook Kim, Dong-Ik Kim, Minsuk Kim, Hyung-Jun Kim, Ohn Soon Kim, Sung Han Kim, Jae Hyun Kim, Sewoon Kim, Sung Tae Kim, Richard Kim, Albert H Kim, Ju Deok Kim, Jin Seok Kim, Chong Ae Kim, Hyun-Ji Kim, Yong Kyung Kim, Eunju Kim, Yun Hye Kim, Sun-Hong Kim, Soyeong Kim, Sowon Kim, Young Sik Kim, Jisun Kim, Mi-Hyun Kim, Haein Kim, Byung-Gyu Kim, Jeonghan Kim, JongKyong Kim, Jin Young Kim, So Ree Kim, Hee Jin Kim, Minjae Kim, Hyun Kim, Kyoung Oh Kim, Jiyea Kim, Jun Hoe Kim, Joon Kim, Sunghwan Kim, Bo-Rahm Kim, Namkyoung Kim, Hee Jeong Kim, Aram Kim, Youn-Jung Kim, Joung Sug Kim, Kangjoon Kim, Hail Kim, Younghoon Kim, Eui Jin Kim, Cheol-Su Kim, Jae Geun Kim, Min Kyeong Kim, Ngoc Thanh Kim, Seong-Seop Kim, Ji-Man Kim, Ju-Kon Kim, Hyeong-Taek Kim, Soo Wan Kim, Woong-Ki Kim, Ju-Wan Kim, Sunggun Kim, Kevin K Kim, Sun Woong Kim, Soeun Kim, Jin Kyong Kim, Hoguen Kim, Sungup Kim, Hyungkuen Kim, Ji Hye Kim, Myoung Hee Kim, Min Ju Kim, Jeong Su Kim, Gwang Sik Kim, Anthony S Kim, Ok Jin Kim, Jeongseop Kim, Bo-Eun Kim, Suk-Kyung Kim, Deok-Ho Kim, Woo-Shik Kim, Sang Soo Kim, Hae Won Kim, Mina K Kim, Kiyoung Kim, Paul H Kim, Taeil Kim, Eun-Kyung Kim, Joonyoung R Kim, Da-Sol Kim, Yeaseul Kim, In Ja Kim, Beomsu Kim, Byungwook Kim, Kyung-Hee Kim, Hyeyoon Kim, Sun Yeou Kim, Hyojin Kim, Jongmyung Kim, Yangseok Kim, Jong Ho Kim, Chunki Kim, Seokjoong Kim, Helen Kim, Sungyeon Kim, Mi Ra Kim, Dae-Eun Kim, Young-Dae Kim, Young Mi Kim, Na-Kuang Kim, Yoon Sook Kim, Jayoun Kim, Byoung Jae Kim, Jung Dae Kim, Joseph Han Sol Kim, Daham Kim, Mijung Kim, Yu Kyeong Kim, Yong-Lim Kim, E-S Kim, Jin-Chul Kim, Chan Wook Kim, Hyeong-Jin Kim, Boo-Young Kim, Sang Hyuk Kim, Sung-Mi Kim, Dongwoo Kim, Seul-Ki Kim, Hye Jin Kim, Gibae Kim, Soo Young Kim, Sang Ryong Kim, Sukjun Kim, Dong Joon Kim, Hyo Jung Kim, Yeseul Kim, Jieun Kim, Jongchan Kim, Joseph C Kim, Yong Sik Kim, Nam-Eun Kim, Jun Pyo Kim, Sang-Tae Kim, Brandon J Kim, Hong Sug Kim, Youngjoo Kim, Sun-Gyun Kim, Min-Gon Kim, Young-Woo Kim, Myungshin Kim, Tae Hoen Kim, Soon Hee Kim, Won Kim, Chanhee Kim, Jung Oh Kim, Jun-Sik Kim, Ji Eun Kim, Hyun-Kyong Kim, Jeffrey Kim, Yeonhwa Kim, Jung-In Kim, Chan-Wha Kim, B-Y Kim, B T Kim, Dahee Kim, Taek-Yeong Kim, Yeon Ju Kim, Duck-Hee Kim, Hyunjoon Kim, Young-Saeng Kim, Seohyeon Kim, Soon Sun Kim, Hyeon Jeong Kim, Jae Bum Kim, Yeul Hong Kim, Hyemin Kim, Shin Kim, Juhyun Kim, Chang-Gu Kim, Y S Kim, Dan Say Kim, Ji-Dam Kim, Gwangil Kim, Alison J Kim, Paul T Kim, Kyoung Hoon Kim, Hwa-Jung Kim, Ye-Ri Kim, Youngeun Kim, Cheol-Hee Kim, Hee-Jin Kim, Jason Kim, Youngsin Kim, NamHee Kim, Hyuk Soon Kim, Byung-Chul Kim, Cecilia Kim, S Kim, Tae-Gyu Kim, Kwan-Suk Kim, Seung-Ki Kim, Jee Ah Kim, Moon Suk Kim, Young Ju Kim, Kyoungtae Kim, Yunwoo Kim, J Y Kim, Lia Kim, Soo-Hyun Kim, Byung Jin Kim, You-Sun Kim, Seong Jun Kim, Youngsoo Kim, Yunkyung Kim, Mi Jeong Kim, Myoung Sook Kim, Meelim Kim, Kye-Seong Kim, Chu-Young Kim, Minseon Kim, Minsu Kim, Hye-Jin Kim, Il-Man Kim, Seong-Tae Kim, Dong Ha Kim, Soo Yoon Kim, Donghyeon Kim, Sunoh Kim, Yu-Jin Kim, Yul-Ho Kim, Stuart K Kim, Eric Kim, Soo Hyun Kim, Jae-Young Kim, Jin Hee Kim, Tae Min Kim, Il-Chan Kim, Mi-Na Kim, Yeji Kim, Yo-Han Kim, Yeong-Sang Kim, Eunmi Kim, Taewan Kim, Kyong-Tai Kim, Dae-Kyeong Kim, Yun Seok Kim, Kyung Hee Kim, M Kim, June Hee Kim, Hyun Eun Kim, Eunkyeong Kim, Tae Hyun Kim, Soee Kim, Young-Im Kim, So-Hee Kim, Hyeong Hoe Kim, Hee Young Kim, Leo A Kim, Eungseok Kim, Sungyun Kim, Young S Kim, Min Bum Kim, Min Seo Kim, Tae-You Kim, Jong-Yeon Kim, Tae Hoon Kim, Sungrae Kim, Eun-Jin Kim, Heejin Kim, Tae Jin Kim, Seong-Jin Kim, Young-Chul Kim, Jinkyeong Kim, SooHyeon Kim, Ju Young Kim, Kwangwoo Kim, Un-Kyung Kim, Dong-Hee Kim, Sang Wun Kim, Jin Woo Kim, Gu-Hwan Kim, Young-Mi Kim, Dae-Kyum Kim, Won J Kim, Seung Won Kim, Tae-Min Kim, Seon-Kyu Kim, Hana Kim, Hye Ran Kim, Ji-Yul Kim, Moo-Yeon Kim, Do Yeon Kim, Jun Seok Kim, Su-Jin Kim, Yuli Kim, Jung Ho Kim, Edwin H Kim, Jewoo Kim, A Ram Kim, Grace Kim, Jongho Kim, Hyung Hoi Kim, Soung Jung Kim, Song-Rae Kim, Jinsup Kim, Dong-Kyu Kim, Su-Hyeong Kim, Hye-Ran Kim, Kee-Tae Kim, Nam-Ho Kim, Yoongeum Kim, Jeong-Han Kim, Jin Gyeom Kim, Jinsoo Kim, Mi Young Kim, Hyun-Sic Kim, Steve Kim, Kyung-Sup Kim, Taeyoung Kim, Hyeonwoo Kim, Dong Gwang Kim, Jong-Youn Kim, Hwi Seung Kim, Doo Yeon Kim, Hye Ree Kim, Hyeong-Geug Kim, Jong-Il Kim, Soo Whan Kim, Kwang-Eun Kim, Jong-Won Kim, Eung-Gook Kim, Jaehoon Kim, Yu Mi Kim, J H Kim, Hyoung Kyu Kim, Hark Kyun Kim, Suk Jae Kim, Sung-Hee Kim, Jonggeol J Kim, Sang Eun Kim, Na-Young Kim, Minji Kim, Jeong Kyu Kim, Jongkyu Kim, Jae-Yoon Kim, Hyunjin Kim, Eun Ji Kim, Youngmi Kim, William Kim, Helen B Kim, Jiho Kim, Dae In Kim, Dennis Y Kim, Sunghun Kim, Nari Kim, Doyeon Kim, Sang-Min Kim, Dong-Yi Kim, Myeong-Kyu Kim, Youngsook Kim, Ji-Yun Kim, Sung Woo Kim, Ha-Jung Kim, Yongmin Kim, Angela H Kim, Han Young Kim, Hye-Jung Kim, Hyun-Soo Kim, Hyunju Kim, Jin Man Kim, Hyung-Suk Kim, Young Nam Kim, Hang-Rai Kim, Hyoun-Ah Kim, Hye Young Kim, Sung-Wan Kim, Sung Yeol Kim, Jong-Oh Kim, Y-D Kim, Jong-Hyun Kim, Myung-Sun Kim, Jenny H Kim, Youngchang Kim, Mi Kyung Kim, Eun Young Kim, Okhwa Kim, Jinhee Kim, Y A Kim, Won Kyung Kim, Hyung-Gu Kim, Dongjoon Kim, Woo Sik Kim, Myung Jin Kim, In Suk Kim, Hannah Kim, Ick Young Kim, Hyunsoo Kim, Sung Eun Kim, Yekaterina Kim, Sungjoo Kim, Seonhee Kim, Y-M Kim, Sun Hee Kim, Juyoung Kim, Jung Sun Kim, Ji Young Kim, Hong-Hee Kim, Hye-Sung Kim, Sung-Eun Kim, Wun-Jae Kim, Ji Hyun Kim, Kyung Mee Kim, Hee Nam Kim, Sunghak Kim, Dong-Hoon Kim, Vladimir Kim, Yong-Wan Kim, Seul Young Kim, Myoung Ok Kim, Jong-Seok Kim, H Kim, Minsik Kim, Sang-Young Kim, Donghee Kim, June-Bum Kim, Dong Hyun Kim, Sang Jin Kim, Jihoon Kim, Won Ho Kim, Byeong-Won Kim, Jaegil Kim, Hyung-Goo Kim, Tae Wan Kim, Seonggon Kim, J Julie Kim, Jiwon Kim, Eun-Joo Kim, Seongho Kim, Hyun Soo Kim, Dong Wook Kim, Tae-Hyoung Kim, Anna Kim, Gahyun Kim, Jun-Hyung Kim, Don-Kyu Kim, Jong Hwan Kim, Kyung An Kim, Jun Suk Kim, Borahm Kim, Caroline Kim, Andrea J Kim, Jung-Lye Kim, Yong-Hoon Kim, Dongkyun Kim, Sung Kyun Kim, Jisup Kim, Yong Kyun Kim, Yerin Kim, Young-Eun Kim, Seung Woo Kim, Jun W Kim, Angela Kim, Eunae Kim, Tae-Eun Kim, Won Tae Kim, Kyung-Sub Kim, Ji Won Kim, Sang Geon Kim, Kang Ho Kim, Young-Cho Kim, Chul Hwan Kim, Bo Young Kim, Yong Sig Kim, Hong-Kyu Kim, Go Woon Kim, Minsoon Kim, Peter K Kim, Taeeun Kim, Eunhyun Kim, Min-Sik Kim, Paul Kim, Jeongseon Kim, Hyejin Kim, Chang-Yub Kim, Kyunggon Kim, Sinai Kim, Tae-Mi Kim, Oc-Hee Kim, Da-Hyun Kim, Jong Geun Kim, Woo Kyung Kim, Jae-Yong Kim, Jiyeon Kim, Jaeuk U Kim, Kye Hyun Kim, Dae-Jin Kim, Chong Kook Kim, Minkyung Kim, Jun Chul Kim, Cecilia E Kim, Jae Seon Kim, Yeon-Jeong Kim, Ha-Neui Kim, Kwan Hyun Kim, Dae Keun Kim, You Sun Kim, Heung-Joong Kim, Jongwan Kim, Angela S Kim, Young Hun Kim, Nam Hee Kim, Jong Yeol Kim, Ji-Young Kim, So-Woon Kim, Dayoung Kim, Sangwoo Kim, Ji-Hoon Kim, Ki Tae Kim, Young-Bum Kim, Eric Eunshik Kim, Hyojung Kim, Yeeun Kim, Jeewoo Kim, Sungmin Kim, Hyun Sil Kim, Young Hee Kim, Woonhee Kim, Minjeong Kim, Sae Hun Kim, Sohee Kim, Kyunga Kim, Donghyun Kim, Sung-Kyu Kim, Hanah Kim, Do-Kyun Kim, Jong-Joo Kim, Sangsoo Kim, Yong-Woon Kim, Jonggeol Jeffrey Kim, Geun-Young Kim, Jae-Jun Kim, Min Soo Kim, K-K Kim, Jung-Taek Kim, Ju Han Kim, Jeeyoung Kim, Hyung Yoon Kim, Min-Sun Kim, Youngchul Kim, Minhee Kim, Byung-Taek Kim, Sung-Bae Kim, Kwang Pyo Kim, Suk-Jeong Kim, Min-A Kim, Ngoc-Thanh Kim, Jae T Kim, Chan-Duck Kim, Dong-Seok Kim, Hyeon Ho Kim, Soo-Youl Kim, Min-Seon Kim, Young Tae Kim, Hyoun Ju Kim, Shi-Mun Kim, Kwang-Pyo Kim, Hee Jong Kim, JungMin Kim, Minah Kim, Taehyoun Kim, Kwonseop Kim, Yonghwan Kim, Kyong Min Kim, Won Dong Kim, Su-Jeong Kim, Jae-Jung Kim, Eunha Kim, Howard H Kim, Min-Hyun Kim, Kyeongjin Kim, Min Kim, Sung Won Kim, Min-Seo Kim, Se-Wha Kim, Myeoung Su Kim, Minjoo Kim, Sujung Kim, Eonmi Kim, In-Hoo Kim, Woo-Kyun Kim, Nan Young Kim, Myeong Ok Kim, Yongjae Kim, Wootae Kim, Jong-Kyu Kim, In Kyoung Kim, Leen Kim, Doo Yeong Kim, Do-Hyung Kim, Dong-il Kim, Jeri Kim, Dong-Hyeok Kim, Seol-A Kim, Soriul Kim, Kil-Nam Kim, Joonseok Kim, Soo-Rim Kim, So Yeon Kim, Kwangho Kim, Yun-Jin Kim, Yeonjung Kim, Seok Won Kim, Bo Ri Kim, Su Jin Kim, TaeHyung Kim, Kyung Woo Kim, Woo Jin Kim, Yeon-Jung Kim, Misun Kim, Serim Kim, Jeong Hee Kim, Youn Shic Kim, Junesun Kim, Dong-Eun Kim, Young Ree Kim, So-Yeon Kim, Choel Kim, Jae Hun Kim, C H Kim, Sung-Hoon Kim, Namphil Kim, Kyung-Chang Kim, Jin-Soo Kim, Jimi Kim, You-Jin Kim, Goun Kim, Goo-Young Kim, Jong Han Kim, Bongjun Kim, Sun-Joong Kim, Sun Hye Kim, Seulhee Kim, Joonyoung Kim, Gunhee Kim, Joungmok Kim, Young Ho Kim, Seung-Whan Kim, Sang-Woo Kim, Seongmi Kim, Kyung Sup Kim, Young Jin Kim, Scott Y H Kim, Chang Seong Kim, Ryung S Kim, Daegyeom Kim, Da Sol Kim, Ellen Kim, Kellan Kim, Young Rae Kim, Hee-Sun Kim, Seung Jun Kim, Han Gyung Kim, Jae Hoon Kim, Kyungjin Kim, Youn-Kyung Kim, Jung-Ha Kim, Sunghoon Kim, Jung-Hyun Kim, Jaeyeon Kim, Hyung-Mi Kim, Young Eun Kim, Hye-Young H Kim, Ho Shik Kim, Ho-Sook Kim, Hyun Ju Kim, Hwijin Kim, Gyeonghun Kim, Kyungtae Kim, Baek Kim, Soon-Hee Kim, David E Kim, Ki Kwon Kim, Joong Sun Kim, Yongae Kim, Jaemi Kim, Hyun-ju Kim, Tai Kyoung Kim, Hoon Seok Kim, Yunjung Kim, Keun You Kim, Se Hyun Kim, Min Cheol Kim, Gye Lim Kim, Hyeseon Kim, Jin Cheon Kim, Hyung-Ryong Kim, Carla F Kim, Hyunki Kim, Dakyung Kim, Yong-Sik Kim, Jong Won Kim, Hoon Kim, Seung-Jin Kim, Myeong Ji Kim, Joonki Kim, NamDoo Kim, Jinho Kim, Hyo Jong Kim, Young-Woong Kim, Un Gi Kim, Tae-Hyun Kim, Hyung-Sik Kim, Ah-Ram Kim, Kee-Pyo Kim, Oh Yoen Kim, Juyeong Kim, Deok Ryong Kim, Jun Hee Kim, Hyunyoung Kim, Jung Ki Kim, Yongkang Kim, Chae-Hyun Kim, Brian S Kim, Minchul Kim, Leo Kim, Eun Ho Kim, Haeryoung Kim, Seong Kim, Jessica Kim, Kahye Kim, Jae-Ryong Kim, Jin Won Kim, Hyun Sook Kim, Kyeongmi Kim, Rosalind Kim, Heegoo Kim, Sujin Kim, In Joo Kim, E Kim, Sung-Jo Kim, Sang Chan Kim, Kyuho Kim, Nam-Hyung Kim, Sin Gon Kim, Sunkyu Kim, Seohyun Kim, Beom-Jun Kim, Boram Kim, Kyeong Jin Kim, Wanil Kim, Gi Beom Kim, Hei Sung Kim, Jason K Kim, Woojin Scott Kim, Hyung-Seok Kim, Won Jeoung Kim, Jungwoo Kim, Dae Hyun Kim, Yejin Kim, Jina Kim, Kyu-Kwang Kim, Yong-Soo Kim, Yong-Ou Kim, M J Kim, Ji-Won Kim, Yoonjung Kim, Chul Hoon Kim, Hyun-Jung Kim, Jae Hyoung Kim, Eui-Soon Kim, Hyun Joon Kim, Minkyeong Kim, M V Kim, Hyun-Jin Kim, Ok-Kyung Kim, Yumi Kim, Kyungsook Kim, Kyungwon Kim, Sunyoung Kim, Jin Kim, Suji Kim, Ok-Hyeon Kim, Maya Kim, Mijeong Kim, Jung-Woong Kim, Seoyeon Kim, Hyunbae Kim, Esl Kim, Kyeong-Min Kim, Sang-Hoon Kim, Hyun Gi Kim, Jooho Kim, Su Kang Kim, Ju-Ryoung Kim, Myung-Jin Kim, Eun-Jung Kim, Sangchul Kim, Bomi Kim, Kyung Han Kim, Seoyoung Kim, Ji-Eun Kim, Yoojin Kim, Joori Kim, Min Jung Kim, Minju Kim, Jeeho Kim, Tae-Woon Kim, Jihye Kim, Jae Gon Kim, Hyeong Su Kim, Choon-Song Kim, Kye Hun Kim, Mi-Young Kim, Choon Ok Kim, Hyesung Kim, Na Yeon Kim, Seong-Ik Kim, Yeon-Ki Kim, Jisu Kim, Jaeyoon Kim, Dong-Hyun Kim, Hyeung-Rak Kim, Myungsuk Kim, Kook Hwan Kim, Eui Hyun Kim, Won-Tae Kim, Sung Soo Kim, Sung Hyun Kim, Eun Kim, Hyung Min Kim, Sol Kim, Jihyun Kim, Hyunwoo Kim, Kwang Dong Kim, Min Joo Kim, Suhyun Kim, Elizabeth H Kim, Sang-Gun Kim, Han-Kyul Kim, Dong-Wook Kim, Young Sam Kim, Yong Deuk Kim, Jong-Seo Kim, Young-Ho Kim, Yoo Ri Kim, Hye-Yeon Kim, Eiru Kim, Ji Yeon Kim, Ki Hyun Kim, Tae Hun Kim, Ae-Jung Kim, Yun Joong Kim, Eosu Kim, Ki Woong Kim, Cheorl-Ho Kim, TaeYeong Kim, Yeon-Hee Kim, Jae Suk Kim, Richard B Kim, Jungsu Kim, Young-Jin Kim, Deokhoon Kim, Eung Yeop Kim, Misu Kim, Seung Chul Kim, Mi-Yeon Kim, K-S Kim, Hyo-Soo Kim, Daeseung Kim, Won Kon Kim, Sangmi Kim, Jong Deog Kim, Yun Gi Kim, Seon-Young Kim, Il-Sup Kim, Ji Hun Kim, Byung Guk Kim, Susy Kim, Youngwoo Kim, Mi-Sung Kim, Min-Young Kim, Jae-Min Kim, Young Woo Kim, Yong Sung Kim, Young-Won Kim, Taehyeung Kim, Meesun Kim, Sook Young Kim, Jaewon Kim, Jung H Kim, In Su Kim, Eun Hee Kim, Yong Kwan Kim, Haelee Kim, Daesik Kim, Heebal Kim, Seungsoo Kim, Bong-Jo Kim, Woo-Jin Kim, Seon Hwa Kim, Luke Y Kim, Jae-Ick Kim, Hwajung Kim, Jisook Kim, Jeffrey J Kim, Kyung Do Kim, Gukhan Kim, Jungeun Kim, Youbin Kim, Jeong-Min Kim, Hyungjun Kim, Young-Hoon Kim, Seokhwi Kim, Jong-Ki Kim, Byron Kim, Taek-Kyun Kim, D-W Kim, Bo-Ra Kim, Dokyoon Kim, Su-Yeon Kim, Min Chul Kim, Jung Hee Kim, Wook Kim, Jun-Mo Kim, Miso Kim, Seong-Min Kim, Jang Heub Kim, Seon Hee Kim, Hong-Gi Kim, Hyun-Young Kim, Young Hwa Kim, Hyeyoung Kim, Hyunwook Kim, Hyung Bum Kim, Dae-Soo Kim, Hee Su Kim, Gitae Kim, Hyun-Yi Kim, Sejoong Kim, Young-Joo Kim, Reuben H Kim, Hong-Kook Kim, Hyungsoo Kim, Soo Jung Kim, Sungryong Kim, Hyunmi Kim, June Soo Kim, Gyudong Kim, Rokki Kim, Yong Sook Kim, Young-Il Kim, Jinsu Kim, Woo-Yang Kim, Eunjoon Kim, Taejung Kim, Woo Kim, Jang-Hee Kim, Won Seok Kim, Jung Soo Kim, Kyoung Hwan Kim, Sung Mok Kim, Seung Tea Kim, Tae Il Kim, Daeeun Kim, Hyelim Kim, Beomsoo Kim, Ji-Woon Kim
Alzheimer's disease (AD) is a complex neurodegenerative disorder characterized by cognitive decline, oxidative stress, neuroinflammation, amyloid-beta (Aβ) accumulation, and tau protein hyperphosphory Show more
Alzheimer's disease (AD) is a complex neurodegenerative disorder characterized by cognitive decline, oxidative stress, neuroinflammation, amyloid-beta (Aβ) accumulation, and tau protein hyperphosphorylation. In this study, we synthesized novel Ramalin derivatives and evaluated their therapeutic potential against AD, focusing on antioxidant, anti-inflammatory, and neuroprotective activities. RA-2OMe, RA-4OMe, RA-2CF3, and RA-4OCF3 showed strong antioxidant effects, while RA-2OMe exhibited potent NO and NLRP3 inhibition (~20%). RA-NAP, RA-PYD, and RA-2Q showed moderate anti-inflammatory activity. BACE-1 inhibition was significant in RA-3CF3, RA-NAP, and RA-PYD, with IC Show less
Seven compounds, comprising three anthraquinones and four stilbenoids, were isolated from the roots of Rheum palmatum L. These compounds include chrysophanol (1), aloe-emodin (2), aloe-emodin 8-O-β-D- Show more
Seven compounds, comprising three anthraquinones and four stilbenoids, were isolated from the roots of Rheum palmatum L. These compounds include chrysophanol (1), aloe-emodin (2), aloe-emodin 8-O-β-D-glucopyranoside (3), desoxyrhapontigenin (4), rhapontigenin (5), desoxyrhaponticin (6), and piceatannol 3'-O-β-D-glucopyranoside (7). Among these, compound 5 showed potent β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitory activity with an IC Show less
Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder characterized by cognitive decline, anxiety-like behavior, β-amyloid (Aβ) accumulation, and tau hyperphosphorylation. BACE1, the Show more
Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder characterized by cognitive decline, anxiety-like behavior, β-amyloid (Aβ) accumulation, and tau hyperphosphorylation. BACE1, the enzyme critical for Aβ production, has been a major therapeutic target; however, direct BACE1 inhibition has been associated with adverse side effects. This study investigates the therapeutic potential of RA-PR058, a novel ramalin derivative, as a multi-targeted modulator of AD-related pathologies. The effects of RA-PR058 were evaluated Show less
Alzheimer's disease (AD) is the most common type of dementia. Its incidence is rising rapidly as the global population ages, leading to a significant social and economic burden. AD involves complex pa Show more
Alzheimer's disease (AD) is the most common type of dementia. Its incidence is rising rapidly as the global population ages, leading to a significant social and economic burden. AD involves complex pathologies, including amyloid plaque accumulation, synaptic dysfunction, and neuroinflammation. This study explores the therapeutic potential of N Show less
Alzheimer's disease (AD) prevention is a critical challenge for aging societies, necessitating the exploration of food ingredients and whole foods as potential therapeutic agents. This study aimed to Show more
Alzheimer's disease (AD) prevention is a critical challenge for aging societies, necessitating the exploration of food ingredients and whole foods as potential therapeutic agents. This study aimed to identify natural compounds (NCs) with therapeutic potential in AD using an innovative bioinformatics-integrated deep neural analysis approach, combining computational predictions with molecular docking and in vitro experiments for comprehensive evaluation. We employed the bioinformatics-integrated deep neural analysis of NCs for Disease Discovery (BioDeepNat) application in the data collected from chemical databases. Random forest regression models were utilized to predict the IC Show less
β-secretase (BACE1) is instrumental in amyloid-β (Aβ) production, with overexpression noted in Alzheimer's disease (AD) neuropathology. The interaction of Aβ with the receptor for advanced glycation e Show more
β-secretase (BACE1) is instrumental in amyloid-β (Aβ) production, with overexpression noted in Alzheimer's disease (AD) neuropathology. The interaction of Aβ with the receptor for advanced glycation endproducts (RAGE) facilitates cerebral uptake of Aβ and exacerbates its neurotoxicity and neuroinflammation, further augmenting BACE1 expression. Given the limitations of previous BACE1 inhibition efforts, the study explores reducing BACE1 expression to mitigate AD pathology. The research reveals that the anticancer agent 6-thioguanosine (6-TG) markedly diminishes BACE1 expression without eliciting cytotoxicity while enhancing microglial phagocytic activity, and ameliorate cognitive impairments with reducing Aβ accumulation in AD mice. Leveraging advanced deep learning-based tool for target identification, and corroborating with surface plasmon resonance assays, it is elucidated that 6-TG directly interacts with RAGE, modulating BACE1 expression through the JAK2-STAT1 pathway and elevating soluble RAGE (sRAGE) levels in the brain. The findings illuminate the therapeutic potential of 6-TG in ameliorating AD manifestations and advocate for small molecule strategies to increase brain sRAGE levels, offering a strategic alternative to the challenges posed by the complexity of AD. Show less
This study aimed to develop and apply a novel computational pipeline combining SELFormer, a transformer architecture-based chemical language model, with advanced deep learning techniques to predict na Show more
This study aimed to develop and apply a novel computational pipeline combining SELFormer, a transformer architecture-based chemical language model, with advanced deep learning techniques to predict natural compounds (NCs) with potential in Alzheimer's disease (AD) treatment. The NCs were identified based on activity related to seven AD-specific genes, including acetylcholinesterase (AChE), amyloid precursor protein (APP), beta-secretase 1 (BACE1), and presenilin-1 (PSEN1). We implemented a computational pipeline using SELFormer and deep learning techniques, conducted optimal clustering and quantitative structure-activity relationship (QSAR) analyses, and performed a uniform manifold approximation and projection (UMAP) to categorize compounds based on bioactivity levels. Molecular docking analysis was carried out on selected compounds. To validate the computational predictions, we conducted in vitro studies using nerve growth factor (NGF)-differentiated PC12 cells. Finally, we mapped the relationships between food sources containing the identified compounds and their target proteins. Optimal clustering analysis revealed five distinct groups of NCs, while QSAR analysis highlighted variations in molecular properties across clusters. The UMAP projection identified 17 highly active NCs (pIC This integrated computational and experimental approach offers a promising framework for identifying potential NCs for AD treatment. The results contribute to exploring effective therapeutic strategies against AD. Show less
Nonalcoholic fatty liver disease is a hepatic condition characterized by excessive fat accumulation in the liver with advanced stage nonalcoholic steatohepatitis (NASH), potentially leading to liver f Show more
Nonalcoholic fatty liver disease is a hepatic condition characterized by excessive fat accumulation in the liver with advanced stage nonalcoholic steatohepatitis (NASH), potentially leading to liver fibrosis, cirrhosis, and cancer. Currently, the identification and classification of NASH require invasive liver biopsy, which has certain limitations. Mass spectrometry-based proteomics can detect crucial proteins and pathways implicated in NASH development and progression. We collected the liver and serum samples from choline-deficient, L-amino acid-defined high-fat diet fed NASH C57BL/6J mice and human serum samples to examine proteomic alterations and identify early biomarkers for NASH diagnosis. In-depth targeted multiple reaction monitoring scanning and immunoblotting assays were used to verify the biomarker candidates from mouse liver and serum samples, and enzyme-linked immunosorbent assay (ELISA) was employed to analyze human serum samples. The multiple reaction monitoring analysis of NASH liver revealed 50 proteins with altered expression (21 upregulated and 29 downregulated) that are involved in biological processes such as detoxification, fibrosis, inflammation, and fatty acid metabolism. Ingenuity pathway analysis identified impaired protein synthesis, cellular stress and defense, cellular processes and communication, and metabolism in NASH mouse liver. Immunoblotting analysis confirmed that the expression of proteins associated with fatty acid metabolism (Aldo B and Fasn) and urea cycle (Arg1, Cps1, and Otc) was altered in the mouse liver and serum. Further analysis on human serum samples using ELISA confirmed the increased expression of multiple proteins, including Aldo B, Asl, and Lgals3, demonstrating values of 0.917, 0.979, and 0.965 of area under the curve in NASH diagnosis. These findings offer valuable insights into the molecular mechanisms of NASH and possible diagnostic biomarkers for early detection. Show less
Senescence of mesenchymal stem cells in bone tissue (BMSCs), the primary progenitors of osteoblasts, is a key contributor to age-related osteopenia and osteoporosis. Aged cells exhibit elevated cellul Show more
Senescence of mesenchymal stem cells in bone tissue (BMSCs), the primary progenitors of osteoblasts, is a key contributor to age-related osteopenia and osteoporosis. Aged cells exhibit elevated cellular stress and abnormal accumulation of stress granules (SGs), which contain G-quadruplex (G4) structured nucleic acids and G4-binding proteins. Dhx36, a helicase that unwinds G4 structure, may play a protective role in this context. In this study, we investigated the function of Dhx36 in BMSCs and bone homeostasis by silencing Dhx36 expression in vitro and in vivo. Dhx36 deficiency increased SG formation and impaired their resolution in BMSCs. This was accompanied by reduced expression of G4-containing autophagyrelated genes and diminished autophagic activity. Loss of Dhx36 also enhanced senescence features and impaired BMSC osteogenic differentiation. Dhx36 expression was significantly lower in bone tissue and BMSCs from aged mice, compared to young mice. Moreover, 8-week-old mice with BMSC-specific Dhx36 knockout exhibited reduced bone volume and trabecular number, indicating premature bone loss. Analysis of public singlecell RNA sequencing data further showed that stress induced by 5-fluorouracil in mice suppressed Dhx36 expression in BMSCs, and downregulated genes related to ossification and osteoblast differentiation. Collectively, our findings identify Dhx36 as a regulator of BMSC aging, linking SG dynamics and autophagy to bone homeostasis, and suggest Dhx36 as a potential therapeutic target to prevent age-related bone loss. [BMB Reports 2025; 58(12): 501-510]. Show less
Several KRASG12D inhibitors (KRASG12Di) are under clinical evaluation for pancreatic ductal adenocarcinoma (PDAC). However, as seen with other first generation KRAS inhibitors, resistance may limit th Show more
Several KRASG12D inhibitors (KRASG12Di) are under clinical evaluation for pancreatic ductal adenocarcinoma (PDAC). However, as seen with other first generation KRAS inhibitors, resistance may limit their long-term efficacy, necessitating combination strategies to enhance therapeutic outcomes. Exportin 1 (XPO1), a nuclear transport protein overexpressed in PDAC, represents a therapeutic vulnerability in KRAS-mutant cancers. Here, we demonstrate that the second-generation XPO1 inhibitor Eltanexor synergizes with MRTX1133 to enhance its efficacy in multiple PDAC models. We generated KRASG12Di-resistant PDAC cells and assessed their response to Eltanexor. The antiproliferative effects of MRTX1133 and Eltanexor combinations were evaluated in 2D and 3D Eltanexor sensitized MRTX1133-resistant PDAC cells to growth inhibition. In both 2D and 3D culture models, the combination of Eltanexor and MRTX1133 significantly reduced cell viability. Mechanistically, the combination treatment suppressed key KRAS downstream signaling molecules, including p-ERK, mTOR, p-4EBP1, DUSP6, and cyclin D1. Kinome analysis further revealed reduced MAPK-related kinase activity. Combining subtherapeutic doses of Eltanexor and MRTX1133 resulted in significant tumor regression and prolonged survival in PDAC xenograft and immunocompetent orthotopic allograft models. Moreover, maintenance therapy with Eltanexor prevented tumor relapse, yielding a durable antitumor response. This study demonstrates that Eltanexor overcomes resistance to MRTX1133 and enhances its efficacy in PDAC. The combination regimen may provide a durable therapeutic response while reducing the required dose of KRASG12D inhibitors, potentially delaying resistance and improving patient outcomes. Show less
Repeated ketamine treatment to maintain a rapid antidepressant effect can lead to side effects over time, highlighting an unmet clinical need for sustaining this drug's antidepressant action from a si Show more
Repeated ketamine treatment to maintain a rapid antidepressant effect can lead to side effects over time, highlighting an unmet clinical need for sustaining this drug's antidepressant action from a single administration. Ketamine-induced synaptic potentiation at CA3-CA1 synapses has been proposed to be a key synaptic substrate for antidepressant action. Here, we found that ketamine-induced CA3-CA1 synaptic potentiation could be augmented by transiently increasing extracellular signal-regulated kinase (ERK) activity through pharmacological inhibition of dual-specificity phosphatases 6 (DUSP6). The antidepressant-like behavioral effects of acute ketamine treatment were extended by DUSP6 inhibition for up to 2 months. The selective deletion of tropomyosin receptor kinase B (TrkB) in excitatory neurons abolished these DUSP6 inhibition-mediated synaptic and behavioral effects. These data suggest that ketamine's rapid antidepressant effects can be sustained by selectively targeting downstream intracellular signaling. Show less
Observational studies have suggested associations between dietary polyunsaturated fatty acids (PUFAs) and cancer risk; however, causal inference regarding skin cancer remains limited due to potential Show more
Observational studies have suggested associations between dietary polyunsaturated fatty acids (PUFAs) and cancer risk; however, causal inference regarding skin cancer remains limited due to potential recall bias, confounding, and reverse causation. This study aimed to evaluate the causal association between genetically predicted circulating PUFA levels and the risk of skin cancers, including basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and melanoma. We conducted a 2-sample Mendelian randomization (MR) study using genome-wide association study summary statistics from the UK Biobank (PUFAs, n=115,006) and the FinnGen consortium (BCC, n=26,272; SCC, n=4,663; melanoma, n=5,753). Genetic instruments were derived for omega-3, docosahexaenoic acid, omega-6, linoleic acid, and the omega-6:3 ratio. Multiple MR methods-including inverse-variance weighted, MR-Egger, weighted median, weighted mode, and MR-PRESSO-were applied to test for consistency and assess pleiotropy and heterogeneity. A higher genetically predicted linoleic acid to total fatty acid ratio was associated with a significantly lower risk of BCC and SCC. Conversely, higher genetically proxied serum omega-3 levels were associated with increased risks of BCC, SCC, and melanoma. The risk effect on SCC was attenuated upon exclusion of rs174528, a variant in the fatty acid desaturase 1 ( This MR analysis supports a causal role of circulating PUFAs in skin cancer development and highlights the importance of FADS-mediated endogenous PUFA metabolism. These findings provide novel insights into the genetic and metabolic underpinnings of skin cancer susceptibility. Show less
This study aimed to infer a causal gene network associated with bone metastasis in lung cancer and to validate its reliability through experimental gene expression analysis. Using DNA microarray data Show more
This study aimed to infer a causal gene network associated with bone metastasis in lung cancer and to validate its reliability through experimental gene expression analysis. Using DNA microarray data from the Gene Expression Omnibus, we analyzed samples from primary lung cancer and those with bone metastasis. Commonly expressed genes in both groups were identified, and a causal network was inferred using Bayesian network inference with Java Objects based on the Bayesian Dirichlet score. To evaluate the network, we predicted the expression changes of downstream genes following knockdown of a key upstream gene and compared these predictions with mRNA expression levels in fatty acid desaturase 1 (FADS1)-knockdown lung cancer cells. The genes FADS1, cardiotrophin-like cytokine factor 1 (CLCF1), chromosome 4 open reading frame 48, sushi, nidogen and EGF like domains 1, FK506-binding protein 15, and coenzyme Q10A (COQ10A) were identified as directly associated with lung cancer bone metastasis. Among them, FADS1 appeared to have a regulatory role, influencing downstream targets. Notably, CLCF1 and COQ10A showed significantly increased expression in FADS1-knockdown cells, consistent with the network's predictions. These findings suggest that Bayesian network analysis is a reliable machine learning approach for uncovering causal gene relationships in cancer metastasis. Furthermore, FADS1 may serve as a potential therapeutic target in lung cancer bone metastasis. The validity of this network was supported by in vitro experiments using a lung cancer cell line. Show less
Identification of drug-repurposing targets with genetic and biological support is an economically and temporally efficient strategy for improving the treatment of diseases. We employed a cross-discipl Show more
Identification of drug-repurposing targets with genetic and biological support is an economically and temporally efficient strategy for improving the treatment of diseases. We employed a cross-disciplinary approach to identify potential therapeutics for the prevention of metabolic-dysfunction-associated steatotic liver disease (MASLD) in at-risk individuals by using humans as a model organism. We identified 212 putative candidate genes associated with MASLD by using data from a large multi-ancestry genetic association study, of which 158 (74.5%) were previously unreported. From this set, we identified 57 genes that encode for druggable protein targets and for which the effects of increasing genetically predicted gene expression on MASLD risk align with the function of that drug on the protein target. We then used We then evaluated these potential targets for evidence of efficacy by using Mendelian randomization, pathway analysis, and protein structural modeling. Through these approaches, we present compelling evidence to suggest that the activation of FADS1 by icosapent ethyl, as well as S1PR2 by fingolimod, could be a promising therapeutic strategy for MASLD prevention. Show less
Identification of drug-repurposing targets with genetic and biological support is an economically and temporally efficient strategy for improving treatment of diseases. We employed a cross-disciplinar Show more
Identification of drug-repurposing targets with genetic and biological support is an economically and temporally efficient strategy for improving treatment of diseases. We employed a cross-disciplinary approach to identify potential treatments for metabolic dysfunction associated steatotic liver disease (MASLD) using humans as a model organism. We identified 212 putative causal genes associated with MASLD using data from a large multi-ancestry genetic association study, of which 158 (74.5%) are novel. From this set we identified 57 genes that encode for druggable protein targets, and where the effects of increasing genetically predicted gene expression on MASLD risk align with the function of that drug on the protein target. These potential targets were then evaluated for evidence of efficacy using Mendelian randomization, pathway analysis, and protein structural modeling. Using these approaches, we present compelling evidence to suggest activation of Show less
Observational studies have demonstrated a close association between polyunsaturated fatty acids (PUFAs) and acne. However, the findings of clinical trials have been inconsistent, leaving the causal re Show more
Observational studies have demonstrated a close association between polyunsaturated fatty acids (PUFAs) and acne. However, the findings of clinical trials have been inconsistent, leaving the causal relationship between PUFAs and acne unclear. To investigate the causal association between genetically proxied PUFAs and acne risk. Mendelian randomization (MR) was performed using single nucleotide polymorphisms associated with PUFAs as instrumental variables. The causal associations between PUFAs and acne were estimated among 115 006 UK Biobank participants and 363 927 participants of Finnish descent. Genetically predicted docosahexaenoic acid (DHA) levels [β = -0.303, 95% confidence interval (CI) -0.480 to -0.126; P = 7.74 × 10-4] and its percentage to total fatty acids (β = -0.402, 95% CI -0.651 to -0.258; P = 5.91 × 10-6) showed a significant causal association with a decreased risk of acne. Conversely, genetically predicted percentages of linoleic acid (LA) in total fatty acids (β = 0.768, 95% CI 0.411-0.126; P = 2.87 × 10-4) and omega-6 : omega-3 ratio (β = 0.373, 95% CI 0.142-0.604; P = 4.48 × 10-3) were robustly associated with an increased risk of acne. These effects were attenuated after excluding a genetic variant of rs174528 located upstream of FADS1, highlighting the biologic link between FADS1 and delta-5 desaturase activity. Multivariable MR analysis indicated that PUFAs were causally associated with acne, independent of body mass index. Our study indicates that high DHA levels and their ratios to total fatty acids have causal protective effects against acne, while high LA levels and omega-6 : omega-3 ratio are associated with increased acne risk. This association was largely attributable to the influence of genetic variants related to FADS1. Show less
Oral squamous cell carcinoma (OSCC) often recurs locally, reducing survival. The oral microbiome may influence tumor recurrence, but its prognostic role is unclear. This study investigated oral microb Show more
Oral squamous cell carcinoma (OSCC) often recurs locally, reducing survival. The oral microbiome may influence tumor recurrence, but its prognostic role is unclear. This study investigated oral microbiomes associated with OSCC recurrence and their prognostic merit. Saliva samples were collected from 133 patients with OSCC. 16S rRNA gene sequencing was performed, and microbial signatures were predicted via XGBoost. Functional metagenomic prediction was conducted using PICRUSt2. XGBoost identified Oral saliva microbiome profiling reveals distinct microbial patterns associated with OSCC recurrence. Our correlation-based functional predictions indicated that the enrichment of Show less
Xenopus embryo serves as an ideal model for teratogenesis assays to observe the effects of any compounds on the cellular processes crucial for early development and adult tissue homeostasis. In our sc Show more
Xenopus embryo serves as an ideal model for teratogenesis assays to observe the effects of any compounds on the cellular processes crucial for early development and adult tissue homeostasis. In our screening of a chemical library with frog embryo, caffeic acid phenethyl ester (CAPE) was found to upregulate the FGF/MAPK pathway, disrupting germ layer formation in early development. Exposure to CAPE interfered with the formation of anterior-posterior body axis and of ectodermal derivatives such as eyes, dorsal fin and pigment cells. These inhibitory effects were achieved by promoting paraxial mesodermal specification and neural differentiation concomitant with a repression of epidermal and neural crest cell fates. This compound also induced the caudalization of anterior neural fate, thereby recapitulating the activity of the FGF/MAPK signals in the anterior-posterior patterning of neural tissue. Consistently, phosphorylation of extracellular signal-regulated kinase (ERK) was elevated in CAPE-treated cells, which was mediated by the FGFR1 and FGFR4 pathway. Together, these results suggest that CAPE functions as an activator of the FGF/MAPK signaling pathway, generating severe teratogenic effects on germ layer specification in vertebrate early development. Show less
Major depressive disorder (MDD) is a complex psychological disorder with a sophisticated molecular etiology. Although its connection with fibroblast growth factor receptor 1 (FGFR1) in the hippocampus Show more
Major depressive disorder (MDD) is a complex psychological disorder with a sophisticated molecular etiology. Although its connection with fibroblast growth factor receptor 1 (FGFR1) in the hippocampus is known, the precise mechanisms underlying its pathophysiology remain unclear. Here we conduct a comprehensive analysis of the molecular profile of the hippocampus in patients with MDD. We identified a distinct overexpression of FGFR1 specifically within the dentate gyrus of patients with MDD. Through the use of optogenetic techniques for the in vivo spatiotemporal dissection of FGFR1 signaling, we uncovered a sequential FGFR1-Notch-brain-derived neurotrophic factor (BDNF) pathway within the dentate gyrus, which can ultimately induce adult hippocampal neurogenesis, significantly contributing to antidepressant effects. We discovered that the dysregulation of this axis by the protein Numb, which demonstrates an age-related increase in individuals with MDD, is closely associated with the development of depressive phenotypes. Remarkably, targeting Numb to restore this axis effectively reversed the depressive phenotype, thus offering new insights into potential therapeutic strategies. Show less
Sex is a key piece of patient information but is often not actively considered in drug use. This is partly due to the lack of molecular evidence at the gene expression level beyond sex chromosomes and Show more
Sex is a key piece of patient information but is often not actively considered in drug use. This is partly due to the lack of molecular evidence at the gene expression level beyond sex chromosomes and sex hormones. We aim to investigate how sex differences in tissue-specific gene expression relate to FDA-approved drugs using the latest database of The Genotype-Tissue Expression (GTEx) V10. Our analysis reveals that 91.4% of FDA-approved drug target genes exhibit sex-differential expression in at least one tissue. The tissues with the most pronounced sex differences include subcutaneous adipose tissue, skeletal muscle, and the pituitary gland, while sex differences are less pronounced in the liver, other brain regions, and the spleen. Sex-differential disease-related genes include those associated with obesity (PPARG, INSR), cancer (FGFR1, CD22), and immunity (IL6R, IL3RA). Based on our findings, we advocate for a policy shift that integrates sex-based molecular data into preclinical studies, drug development, and clinical practices. This paradigm aligns biomedical research with precision medicine, mitigates drug-related risks, and promotes equitable healthcare outcomes. Show less
Fibroblast growth factor receptors (FGFRs) are well-established oncology targets, with aberrant FGFR2 and FGFR3 activation implicated in multiple tumor types, including cholangiocarcinoma and urotheli Show more
Fibroblast growth factor receptors (FGFRs) are well-established oncology targets, with aberrant FGFR2 and FGFR3 activation implicated in multiple tumor types, including cholangiocarcinoma and urothelial carcinoma. Currently approved FGFR2/3-targeted therapies rely on pan-FGFR small-molecule kinase inhibitors, which often lead to off-target toxicities due to unintended inhibition of FGFR1 and FGFR4, as well as acquired resistance driven by gatekeeper mutations. Herein, we report the discovery of INCB126503, a highly potent, orally bioavailable FGFR2/3 inhibitor with excellent isoform selectivity and equipotent activity against gatekeeper mutants. INCB126503 effectively suppresses FGFR signaling in vivo without inducing hyperphosphatemia and demonstrates significant antitumor efficacy in xenograft models harboring FGFR3 genetic alterations. Show less
Recent studies have highlighted the deleterious role of high phosphate intake in hypertension via sympathetic overactivation, yet the underlying mechanisms remain unclear. Dietary phosphate loading tr Show more
Recent studies have highlighted the deleterious role of high phosphate intake in hypertension via sympathetic overactivation, yet the underlying mechanisms remain unclear. Dietary phosphate loading triggers physiologic release of FGF23 (fibroblast growth factor-23) from the bone to maintain phosphate homeostasis. Both FGF23 and FGF receptors (FGFRs) are present in the central nervous system, but their role in neural control of blood pressure during phosphate loading is unknown. We investigated central FGF23/FGFR signaling in high-phosphate diet-induced sympathetic dysregulation of blood pressure in rats. FGF23 protein levels were measured by immunoprecipitation, immunoblotting, and immunohistochemistry. FGF23 translocation into the brain was determined by injecting infrared-labeled FGF23 intravenously into anesthetized Sprague-Dawley rats. Mean arterial pressure (MAP) and renal sympathetic nerve activity (RSNA) responses to hindlimb muscle contraction were measured in decerebrate Sprague-Dawley rats treated with either a normal 0.6% phosphate diet (NP) or a high 1.2% phosphate diet (HP) for 12 weeks before and after intracerebroventricular (ICV) administration of FGFR signaling inhibitors. Excess phosphate intake significantly increased FGF23 protein levels in the brainstem (HP versus NP, Our data reveal a novel pathophysiologic paradigm of high-phosphate diet-induced sympathoexcitation and hypertension by FGF23 crossing into the brain, possibly acting via FGFR4. Show less
SH003, a novel herbal mixture consisting of NSCLC cell lines (A549, H460, HCC827) were treated with SH003 to evaluate cell viability (MTT assay), colony formation, apoptosis (Annexin V/7-AAD staining, Show more
SH003, a novel herbal mixture consisting of NSCLC cell lines (A549, H460, HCC827) were treated with SH003 to evaluate cell viability (MTT assay), colony formation, apoptosis (Annexin V/7-AAD staining, western blot), and cell cycle distribution (PI staining). Phosphorylation of RTKs and related signaling molecules was analyzed using a phospho-RTK array and western blot. NSCLC cell lines A549, H460, and HCC827 treated with SH003 showed significant, dose-dependent cell viability and colony formation reductions. SH003 induced apoptosis, evidenced by increased cleaved PARP and caspase-8 levels, and caused G SH003 is a promising multi-target therapeutic agent for NSCLC, offering a novel strategy to improve patient outcomes. Show less
Xenopus embryo is an ideal model for teratogenesis assays to assess the effects of any compounds on the cellular processes crucial for early development and adult tissue homeostasis. In our screening Show more
Xenopus embryo is an ideal model for teratogenesis assays to assess the effects of any compounds on the cellular processes crucial for early development and adult tissue homeostasis. In our screening of a chemical library with frog embryo to identify novel compounds that exert specific effects on key cellular signaling pathways, perillic acid (PA) was found to disrupt germ layer specification in early development. Thus, the mechanism underlying this effect was investigated. Embryos were exposed to PA during a specific period of early development to observe stage-specific morphological alterations induced by this compound. Whole-mount in situ hybridization was performed to examine its effects on ectodermal and mesodermal differentiation and the anterior-posterior patterning of neural tissue. Western blotting analysis was employed to identify the signaling pathways through which PA influences germ layer formation in Xenopus development. PA-treated embryos exhibited the shortening of the anterior-posterior body axis, truncation of craniofacial structures and malformation of neural crest (NC). These severe morphological defects occurred when embryos became exposed to PA during the gastrula stages. Consistent with these phenotypes, treatment with PA caused significant expansion of neural tissue concomitant with a reduction of epidermal and NC cell fates. Furthermore, PA induced the caudalization of neural fate and expressions of paraxial mesodermal genes, recapitulating the activity of the FGF/MAPK signals in germ layer specification. In line with this, ERK activation could be induced by PA treatment, which was mediated by the FGFR1 pathway. PA affects the anterior-posterior neural patterning and mesodermal specification by activating the FGF/MAPK signaling pathway. Show less
The development of cerebral infarction is multifactorial, including both environmental and genetic factors. This study assessed the association between fibroblast growth factor (FGF)-related gene poly Show more
The development of cerebral infarction is multifactorial, including both environmental and genetic factors. This study assessed the association between fibroblast growth factor (FGF)-related gene polymorphisms and the incidence of cerebral infarction among patients on direct oral anticoagulants (DOACs). Patients over 18 years old with atrial fibrillation who were receiving DOACs for cerebral infarction prevention at Ewha Womans University Mokdong Hospital and Ewha Womans University Seoul Hospital were enrolled in this analysis. Twenty-one single nucleotide polymorphisms (SNPs) from FGF1, FGF2, and FGFR1 were examined. In multivariable logistic regression analysis, three models (Model I: demographic factors only, Model II: demographic factors and genetic factors, and Model III: genetic factors and the CHA Among the 536 candidate patients, 21 (3.9 %) experienced cerebral infarction while taking DOACs. From Model I and Model II, age ≥ 75 years and previous thromboembolic event history increased the risk of cerebral infarction. For genetic factors in Model II and III, FGF1 rs1596776 GG, FGFR1 rs6996321 AA, and FGFR1 rs7012413 TT genotypes were associated with a higher risk of cerebral infarction. The area under the receiver operating curve increased from 0.747 (Model I) to 0.822 (Model II) by adding genetic factors, demonstrating better model performance. This study uncovered the association between FGF-related gene polymorphisms and cerebral infarction among patients with atrial fibrillation undergoing DOAC therapy. Show less